A Multicenter, Randomized, Open-label, Two-arm, Phase 4 Study to Evaluate the Effect of Add-on Pioglitazone or Glimepiride in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled by Alogliptin and Metformin Therapy
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 24 Jan 2019
At a glance
- Drugs Alogliptin/pioglitazone (Primary) ; Alogliptin; Glimepiride; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms EPIDOTE
- Sponsors Takeda
- 16 Jan 2019 Planned initiation date changed from 15 Jan 2019 to 31 Aug 2019.
- 07 Sep 2018 Planned initiation date changed from 13 Jul 2018 to 15 Jan 2019.
- 31 Aug 2018 Biomarkers information updated